Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-08-2008 | Original Article

¹⁸F-FDG PET/CT in sarcoidosis management: review and report of 20 cases

Authors: Jean Jacques Braun, Romain Kessler, André Constantinesco, Alessio Imperiale

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2008

Abstract

Purpose

To evaluate the interest of ¹⁸F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) for diagnosis and therapeutic follow-up of patients with sarcoidosis.

Methods

Twenty consecutive patients with biopsy-proven sarcoidosis were retrospectively included, in particular, 13 and seven cases of thoracic and extra-thoracic sarcoidosis, respectively. All patients underwent ¹⁸F-FDG PET/CT, and 12 of them also ⁶⁷Ga scintigraphy. Five patients were re-examined by ¹⁸F-FDG PET/CT to assess response to corticosteroid (CS) treatment.

Results

Sensitivity of ¹⁸F-FDG PET/CT in detecting active sarcoidosis localizations was determined considering only biopsy-proven sites. For thoracic, sinonasal, and pharyngo-laryngeal localizations, ¹⁸F-FDG PET/CT sensitivity was 100%, 100%, and 80%, respectively. Overall sensitivity for all 36 biopsy-proven localizations improved from 78% to 87% after excluding skin involvement. Considering only the 12 patients who underwent both scintigraphic examinations, overall sensitivity of ⁶⁷Ga scintigraphy and ¹⁸F-FDG PET/CT was 58% and 79%, respectively and improved to 67% and 86% after excluding all sites of skin involvement. To evaluate the efficacy of CS treatment, five enrolled patients underwent second ¹⁸F-FDG PET/CT. Complete regression of all foci of pathological tracer uptake was showed in two cases, permitting CS withdrawal after 2 and 6 months. Improvement but incomplete regression of mediastino-pulmonary disease occurred in two patients treated with CS for 19 and 21 months. Disease progression was assessed in one patient treated with decreasing doses of CS during 16 months.

Conclusion

¹⁸F-FDG PET/CT allows to obtain a complete morpho-functional cartography of inflammatory active localizations and to follow treatment efficacy in patients with sarcoidosis, particularly in atypical, complex, and multisystemic forms.

Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111–8.PubMedCrossRef

Schwartzbauer HR, Tami TA. Ear, nose and throat manifestations of sarcoidosis. Otolaryngol Clin N Am. 2003;36:673–84.CrossRef

Braun JJ, Gentine A, Pauli G. Sinonasal sarcoidosis: review and report of fifteen cases. Laryngoscope. 2004;114:1960–3.PubMedCrossRef

Aubart FM, Ouayoun M, Brauner M, Attali P, Kambouchner M, Valeyre D, et al. Sinonasal involvement in sarcoidosis. Medicine. 2006;85:365–71.PubMedCrossRef

Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42:1S–93S.PubMed

Teirstein AS, Machac J, Almeida O, Lu P, Padilla M, Iannuzzic MC. Results of 188 whole-body FDG PET scans in 137 patients with sarcoidosis. Chest. 2007;132:1949–53.PubMedCrossRef

Meller J, Sahlmann CO, Scheel AK. ¹⁸F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007;48:35–45.PubMed

Kaira K, Ishizuka T, Yanagitani N, Sunaga N, Hisada T, Mori M. Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis. Clin Nucl Med. 2007;32:114–6.PubMedCrossRef

Nguyen BD. F-18 FDG PET imaging of disseminated sarcoidosis. Clin Nucl Med. 2007;32:53–4.PubMedCrossRef

10.

Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K, et al. Comparative evaluation of ¹⁸F-FDG PET and ⁶⁷Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006;47:1571–6.PubMed

11.

Klech H, Kohn H, Kummer F, Mostbeck A. Assessment of activity in sarcoidosis. Chest. 1982;82:732–8.PubMedCrossRef

12.

Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, et al. Positron emission tomography imaging in non malignant thoracic disorders. Semin Nucl Med. 2002;32:293–321.PubMedCrossRef

13.

Alavi A, Buchpiguel CA, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis. J Nucl Med. 1994;35:1650–2.PubMed

14.

Brudin LH, Valind SO, Rhodes CG, Pantin CF, Sweatman M, Jones T, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med. 1994;21:297–305.PubMedCrossRef

15.

Alavi A, Palevsky HI. Gallium-67-citrate scanning in the assessment of disease activity in sarcoidosis. J Nucl Med. 1992;33:751–5.PubMed

16.

Baughman RP, Fernandez M, Bosken CH, Mantil J, Hurtubise P. Comparison of gallium-67 scanning, bronchoalveolar lavage and serum angiotensin–converting enzyme levels in pulmonary sarcoidosis: predicting response to therapy. Am Rev Respir Dis. 1984;129:676–81.PubMed

17.

Lawrence EC, Teague RB, Gottlieb MS, Jhingran SG, Lieberman J. Serial changes in markers of disease activity with corticosteroid treatment in sarcoidosis. Am J Med. 1983;74:747–56.PubMedCrossRef

18.

El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med. 2004;34:313–29.PubMedCrossRef

19.

Koyama T, Ueda H, Togashi K, Umeoka S, Kataoka M, Nagai S. Radiologic manifestations of sarcoidosis in various organs. RadioGraphics. 2004;24:87–104.PubMedCrossRef

20.

Loehrl TA, Smith TL. Inflammatory and granulomatous lesions of the larynx and pharynx. Am J Med. 2001;111:113–7.CrossRef

21.

Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. RadioGraphics. 2005;25:1357–68.PubMedCrossRef

22.

Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7:57–69.PubMedCrossRef

23.

Xiu Y, Yu JQ, Cheng A, Kumar R, Alavi A, Zhunang H. Sarcoidosis demonstrated by FDG PET imaging with negative findings on gallium scintigraphy. Clin Nucl Med. 2005;30:193–5.PubMedCrossRef

24.

Vento JA, Arici M, Spencer RP, Sood R. F-18 FDG PET: mottled splenomegaly with remission of symptoms after splenectomy in sarcoidosis. Clin Nucl Med. 2004;29:103–4.PubMedCrossRef

25.

Kaira K, Oriuchi N, Otani Y, Yanagitani N, Sunaga N, Hisada T, et al. Diagnostic usefulness of fluorine-18-a-methyltyrosine positron emission tomography in combination with F-fluorodeoxyglucose in sarcoidosis patients. Chest. 2007;131:1019–27.PubMedCrossRef

Title: 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases
Authors: Jean Jacques Braun
Romain Kessler
André Constantinesco
Alessio Imperiale
Publication date: 01-08-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0770-9

At a glance: The STEP trials

Springer Medicine

¹⁸F-FDG PET/CT in sarcoidosis management: review and report of 20 cases

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2008

Whole body 18fluoro-l-dopa PET–CT: a useful tool for location and surgical guidance in primary carcinoid tumours

Performance of integrated FDG–PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG–PET/non-contrast-enhanced CT and enhanced CT

Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer

Effects of AV delay programming on ventricular resynchronisation: role of radionuclide ventriculography

Quality of planar whole-body bone scan interpretations—a nationwide survey

PET-CT—comments on the white paper